* This is the Professional Version. *
Spontaneous Bacterial Peritonitis (SBP)
Spontaneous bacterial peritonitis (SBP) is infection of ascitic fluid without an apparent source. Manifestations may include fever, malaise, and symptoms of ascites and worsening hepatic failure. Diagnosis is by examination of ascitic fluid. Treatment is with cefotaxime or another antibiotic.
SBP is particularly common in cirrhotic ascites, especially among alcoholics. This infection can cause serious sequelae or death. The most common bacteria causing SBP are gram-negative Escherichia coli and Klebsiella pneumoniae and gram-positive Streptococcus pneumoniae; usually only a single organism is involved.
Patients have symptoms and signs of ascites. Discomfort is usually present; it typically is diffuse, constant, and mild to moderate in severity.
Signs of SBP may include fever, malaise, encephalopathy, worsening hepatic failure, and unexplained clinical deterioration. Peritoneal signs (eg, abdominal tenderness and rebound) are present but may be somewhat diminished by the presence of ascitic fluid.
Clinical diagnosis of SBP can be difficult; diagnosis requires a high index of suspicion and liberal use of diagnostic paracentesis (see Abdominal Paracentesis), including culture. Transferring ascitic fluid to blood culture media before incubation increases the sensitivity of culture to almost 70%. PMN count of > 250 cells/μL is diagnostic of SBP. Blood cultures are also indicated. Because SBP usually results from a single organism, finding mixed flora on culture suggests a perforated abdominal viscus or contaminated specimen.
If SBP is diagnosed, an antibiotic such as cefotaxime 2 g IV q 4 to 8 h (pending Gram stain and culture results) is given for at least 5 days and until ascitic fluid shows < 250 PMNs/μL. Antibiotics increase the chance of survival. Because SBP recurs within a year in up to 70% of patients, prophylactic antibiotics are indicated; quinolones (eg, norfloxacin 400 mg po once/day) are most widely used.
Antibiotic prophylaxis in ascitic patients with variceal hemorrhage decreases the risk of SBP.
Drug NameSelect Trade
* This is a professional Version *